You have 9 free searches left this month | for more free features.

City

Shanghai (1)

Condition

HER2 (1)

Non Small Cell Lung Cancer (1)

Non-Muscle Invasive Bladder Cancer (1)

Overall Status

Active, not recruiting (1)

Not yet recruiting (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

RemeGen Co., Ltd. (1)

RenJi Hospital (1)

Collaborator

BeiGene (1)

RemeGen Co., Ltd. (1)

Intervention

rc48 (2)

tislelizumab (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

rc48

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Non-Muscle Invasive Bladder Cancer, HER2 Trial (RC48, Tislelizumab)

Not yet recruiting

Non-Muscle Invasive Bladder Cancer
HER2

RC48
Tislelizumab

(no location specified)

Jul 16, 2023

Non Small Cell Lung Cancer Trial in Shanghai (RC48)

Active, not recruiting

Non Small Cell Lung Cancer

RC48

Shanghai, Shanghai, China

Shanghai Pulmonary Hospital

Jan 26, 2022